Phase II Randomized Study Evaluating a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer

Background:
The presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the administration of specific immune-therapies can lead to remarkable antitumor responses supports that lymphocytes play a critical role in cancer immunity.
TIL-based ACT (Adoptive cell therapy using tumor-infiltrating lymphocytes product) is a modality of ACT used to treat patients with multiple types of cancer and it consists in the adoptive transfer of ex vivo expanded autologous tumor-infiltrating lymphocytes obtained from tumor resection or tumor biopsies in patients following a non-myeloablative lymphodepleting (NMA-LD) chemotherapy. Ex vivo expansion of TIL relies on the non-specific expansion of lymphocytes present in tumor single cell suspensions or tumor fragments in high dose IL-2.
Although proven efficacy in selected, the HD-IL-2 use remains relatively restricted due to toxicity. Due to the short serum half-life and the need to achieve an immune-modulatory effect in the tissues, IL-2 must be given in doses that induce severe systemic toxicities, including capillary leak syndrome (CLS), pulmonary edema, hypotension, acute renal insufficiency, and rarely myocarditis, limiting its applicability in cancer. Studies comparing HD-IL-2 with lower doses both in renal cell carcinoma and metastatic melanoma to minimize toxicity demonstrated the superiority of the high dose regimens in both diseases. These drawbacks of HD-IL-2 use encouraged the development of improved IL-2-based biologic agents with higher selectivity for effector immune cell subsets, reduced toxicity, and prolonged half-life.
ANV419 is a novel IL-2 agent, which has been developed as a preferentially IL-2Rβγ directed fusion protein with a longer half-life. It has shown high effector selectivity and a favorable safety profile in preclinical testing, including in nonhuman primates, and it has been investigated in an ongoing open-label, dose-escalation Phase I Study in multiple tumor types. he safety profile of ANV419 is characterized by pyrexia, nausea, vomiting, ALT/AST changes and CRS in some patients. Most events are low grade and self-limiting and manageable with standard supportive care. ANV419 was well-tolerated by most patients. No patient discontinued treatment due to treatment related AE.
Taking all the previous information into account, the primary objectives of this study are:
1. To determine whether TIL-ACT using the IL-2 analog ANV419 reduces the mean number of predefined grade ≥3 relevant adverse events related to interleukin use (based on Common Terminology Criteria for Adverse Events v5.0 - CTCAE v5.0) compared to TIL-ACT using HD-IL-2.
2. To determine whether TIL-ACT using the IL-2 analog improves patient´s reported outcomes (PRO) compared to TIL-ACT using HD-IL-2

开始日期2024-12-01

申办/合作机构

Vall d'Hebron Institut d'Oncologia

[+1]

NCT05641324 / Terminated临床1期

A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma (OMNIA-2)

The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.

开始日期2023-02-10

申办/合作机构

Anaveon AG

NCT05578872 / Completed临床1/2期

A Phase 1/2 Study of ANV419 As Monotherapy or in Combination with Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients with Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)

The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma.

开始日期2022-12-16

申办/合作机构

Anaveon AG

100 项与 ANV-419 相关的临床结果

登录后查看更多信息

100 项与 ANV-419 相关的转化医学

登录后查看更多信息

100 项与 ANV-419 相关的专利（医药）

登录后查看更多信息

项与 ANV-419 相关的文献（医药）

2024-12-31·mAbs

Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy

Article

作者: Regnier, Catherine ; Rondeau, Jean-Michel ; Popp, Simone ; Katopodis, Andreas ; Egli, Nicole ; Richter, Kirsten ; Huber, Christoph ; Murer, Patrizia ; Petersen, Laetitia ; Brannetti, Barbara

Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivity toward effector over regulatory T cells and reducing dose-limiting toxicities. Here we describe ANV419, an IL-2/anti-IL2 antibody fusion protein designed for selective IL-2 receptor βγ (IL-2 Rβγ) activation by sterically hindering IL-2 from binding to IL-2 Rα. The fusion protein has an IL-2 connected to the light chain complementarity-determining region (CDR) domain of a humanized antibody that binds to IL-2 at the same epitope as IL-2 Rα. Optimization of the selectivity and pharmacological properties led to the selection of ANV419. ANV419 preferentially expands CD8⁺ T cells and natural killer (NK) cells over T_regs and can be safely administered at doses that elicit strong pharmacodynamic effects and efficacy in mouse tumor models. Its anti-tumor efficacy was enhanced when combined with programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint inhibitors. ANV419 also enhances the NK cell killing capacity and increases tumor growth inhibition when used alongside trastuzumab in a Her-2⁺ xenograft mouse model. In cynomolgus monkeys, the estimated half-life of ANV419 is 24 h, and doses that induced sustained expansion of effector cells were well tolerated without the severe toxicities typically observed with high-dose IL-2. These data support the clinical development of ANV419 in solid tumors and hematological malignancies as monotherapy and in combination with checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity. ANV419 is currently in Phase 1/2 clinical development and may provide cancer patients with a wider therapeutic window than aldesleukin.

2024-05-01·Journal for ImmunoTherapy of Cancer

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Article

作者: Danlos, Francois-Xavier ; Combarel, David ; Champiat, Stephane ; Ponce, Santiago ; Ouali, Kaissa ; Delahousse, Julia ; Marabelle, Aurelien ; Broutin, Sophie ; Mathiot, Laurent ; Loriot, Yohann ; Cagnat, Justin

Patients with advanced cancer, previously treated with immune checkpoint blockade therapy, may retain residual treatment when undergoing the initial infusion of experimental monotherapy in phase 1 clinical trials. ANV419, an antibody-cytokine fusion protein, combines interleukin-2 (IL-2) with an anti-IL-2 monoclonal antibody, aiming to stimulate the expansion of CD8 T and natural killer lymphocytes while restricting regulatory T lymphocytes. In the recent publication of the phase 1 dose escalation study of ANV419, a notable gap exists in detailed information regarding patients’ prior antitumoral treatments, specifically programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) targeted monoclonal antibodies. Some patients likely retained residual anti-PD-1/PD-L1 monoclonal antibodies, potentially influencing the outcomes of ANV419. In a separate clinical cohort, we retrospectively measured the residual concentration of nivolumab and pembrolizumab, revealing persistent serum concentrations of anti-PD-1/PD-L1 antibodies even months after treatment cessation. This underscores the importance of comprehensively documenting prior immunotherapy details in clinical trials. Such information is crucial for understanding potential interactions that may impact both immunological and clinical effects.

2023-11-01·Journal for immunotherapy of cancer

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Article

作者: Sanchez Perez, Vicky ; Bucher, Christoph ; Corral de la Fuente, Elena ; Joerger, Markus ; Calvo, Emiliano ; Jethwa, Sangeeta ; Alonso, Guzmán ; Lopez, Juanita ; Garralda, Elena ; Hess, Dagmar ; Laubli, Heinz ; König, David

Background:

ANV419 is a stable antibody–cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding of IL-2 to the α subunit of its receptor but has selective affinity for the receptor βγ subunits. Thus, ANV419 preferentially stimulates CD8+effector T cells and natural killer cells which are associated with tumor killing, while minimizing the activation of immunosuppressive regulatory T cells.

Methods:

ANV419-001 is an open-label, multicenter, phase 1 study to evaluate the safety, tolerability, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of ANV419. Secondary objectives were to characterize the pharmacokinetics, pharmacodynamics and tumor response. Adult patients with advanced solid tumors and disease progression after ≥1 previous line of systemic therapy were enrolled. ANV419 was administered by intravenous infusion once every 2 weeks, with a planned treatment duration of 12 months. The dose escalation part of the study explored doses 3, 6 and 12 µg/kg as single patient cohorts followed by 24–364 µg/kg in a 3+3 design. Interim results are reported here (data cut-off: March 22, 2023).

Results:

Forty patients were enrolled and received at least one dose of ANV419. The MTD and RP2D were determined to be 243 µg/kg. The most common ANV419-related treatment-emergent adverse events were Grade 1 and 2 fever (31 (77.5%)), chills (23 (57.5%), vomiting (14 (35.0%)), cytokine release syndrome and nausea (12 (30.0%) each). Transient and self-limiting lymphopenia due to lymphocyte redistribution was observed in all patients. In the RP2D cohort, Grade ≥3 thrombocytopenia and fever were reported by one patient (12.5%) each. All events were manageable with standard supportive care. At doses of 243 µg/kg (RP2D/MTD), the estimated T1/2was approximately 12 hours. At ANV419 doses ≥108 µg/kg, 64% of patients had a best response of at least SD (15 SD and 1 confirmed PR).

Conclusions:

ANV419 at doses up to 243 µg/kg (the RP2D) was well tolerated and showed signs of antitumor activity in a heavily pretreated patient population with advanced solid tumors.

Trial registration number:

NCT04855929.

项与 ANV-419 相关的新闻（医药）

2024-10-30

·PipelineReview

Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting

– First presentation of ANV700, a targeted IL-21 employing proximity activated potentiation of cytokine signaling – – New mechanistic data provide insights into the mode of action of ANV600, currently in clinical development – BASEL, Switzerland I October 30, 2024 I Anaveon, a clinical stage, immuno-oncology company, today announced that it will present posters on ANV700 and ANV600 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held from Friday, November 8, 2024, to Sunday, November 10, 2024, in Houston, Texas. “ANV700 is a novel powerful PD-1 targeted therapeutic which focuses IL-21 signaling on T cells in the tumor microenvironment with the potential to reverse exhaustion,” said Christoph Huber, Chief Scientific Officer of Anaveon . “We will further develop this molecule towards clinical studies to determine the therapeutic benefit in patients.” Posters will be available on the virtual meeting platform and at anaveon.com beginning Nov. 7 at 9 a.m. CST. Details of the poster presentations: Saturday, Nov. 9, 12:15 – 1:45 pm CST Poster #960 Title: ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells Authors: A. Rau, N. Egli, P. Murer, L. Petersen, C. Stocker, K. Richter, C. Huber Poster #954 Title: ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4+ and CD8+ tumor-specific T cells by acting in the tumor microenvironment and draining lymph nodes Authors: P. Murer, A. Zurbach, L. Petersen, N. Egli, A. Katopodis, C. Huber Anaveon is developing selective cytokine receptor agonists with the potential to therapeutically enhance a patient’s immune system to respond to tumors. ANV419, currently in Ph II studies in multiple cancer indications, is designed to preferentially signal through the IL-2 beta/gamma receptor resulting in strong proliferation of effector cells in patients. The follow-on compound, ANV600, targets the selective IL-2 receptor moiety to intratumoral effector cells and may have therapeutic benefit in less immunogenic tumors. These novel types of therapeutics, if approved, could potentially have a wide utility in oncology, including in combination with checkpoint inhibitors, cell therapies, vaccines, and radiotherapy. About Anaveon: Anaveon is a biotechnology company located in Basel, Switzerland. Using our immunological knowledge and expertise in protein engineering, we develop medicines to deliver meaningful benefits to cancer patients. Our lead compounds, ANV419 and ANV600, are currently in clinical trials in solid tumors. Find out more at > anaveon.com SOURCE: Anaveon

免疫疗法AACR会议临床2期临床1期

2024-07-30

·GlobeNewswire-Health Care

Anaveon appoints Dieter Weinand as Chair of its Board of Directors

BASEL, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dieter Weinand, former Chair and CEO of Bayer Pharmaceuticals, as Chair of its Board of Directors. Martin Murphy, who served as Chair since 2019, has stepped down from the Board. “We are pleased to welcome Dieter to Anaveon’s Board. He brings a wealth of strategic and operational experience to Anaveon as we look to advance our lead solid tumor programs through clinical studies and expand our pipeline with novel drug candidates,” said Andreas Katopodis, Chief Executive Officer at Anaveon. “We are greatly indebted to Martin for his contributions and guidance as Chair since the founding of the Company and wish him every success in the future.” “I am very pleased to become Chair of the Board for Anaveon, a company I believe has the potential to make a significant difference in the lives of patients,” said Dieter Weinand. “I look forward to working together with Andreas and the Anaveon team to advance the company through its next stages of growth and to achieve its strategic business and pipeline objectives.” Dieter Weinand is an experienced business leader in the pharmaceutical industry and is the former Chair and CEO of Bayer Pharmaceuticals. During a career stretching back over 30 years he has held various responsibilities in general management, commercial, operational and strategic leadership roles, leading business operations in the Asia-Pacific region, Europe, the Middle East, Africa, Latin America and the United States for companies including Bayer, Pfizer, Bristol-Myers Squibb, and Sanofi. He has also led the development, launch, and commercialization of products in various therapeutic areas, including cardiovascular diseases, oncology, dermatology, immunology, and respiratory and inflammatory diseases. He is currently Chair of the Board of Replimune (REPL), Umoja, and Inspirna, and Executive Chair of the Board of Mnemo Therapeutics as well as serving on the Board of Meliora Therapeutics. He earned an M.S. in pharmacology and toxicology from Long Island University, New York, and a B.A. in biology from Concordia College, New York. Media contact:JW Communications Julia Wilson Email: julia.wilson@anaveon.comTel: +44 (0)7818 430877 About Anaveon:Anaveon is a biotechnology company located in Basel, Switzerland. Using our immunological knowledge and expertise in protein engineering, we develop medicines to deliver meaningful benefits to cancer patients. Our lead compounds, ANV419 and ANV600, are currently in clinical trials in solid tumors. Find out more at > anaveon.com

高管变更

2024-07-22

·药智网

「蛋白偶联」创新：细胞因子只是开始，PEG/mPEG修饰才是未来

有目共睹，ADC药物已是继PD-1单抗肿瘤药之后，肿瘤研发领域的最大热点。而随着越来越多ADC药物的持续上市，全球ADC市场规模也在快速增长。但是，ADC药物逐渐内卷的竞争趋势下，在价值百亿的ADC市场赛道中，如何跑出差异化，却成为每个玩家都迫切面临的难题。为此，有的企业选择在靶向分子上下功夫，避开抗体，以多肽、小分子等新的靶向载体为突破，诞生了PDC、SMDC等区别于ADC的技术类型；而另一些企业却将差异化目光放到了有效载荷之上，利用有效载荷的多样化来凸显差异化。比如以放射性核素、PROTAC分子作为有效载荷的新技术，以各种“药效蛋白”作为治疗性payload的大胆尝试。蛋白效应偶联物优势明显所谓蛋白效应偶联物，即将药效蛋白（细胞因子、蛋白毒素与免疫细胞）与靶向性分子链接在一起，在原来药效蛋白的基础上增加靶向性或其他，减少药效蛋白的系统性毒性，其原理上与熟知的ADC机理相似，在兼具了药效蛋白与偶联药物的特点的同时，也有其特殊优势：相较传统药效蛋白，蛋白效应偶联物理论上可以拥有更强的有效性、更低的毒副作用、更特异性的靶点与更高的效价，当其与化疗、放疗等其他抗肿瘤治疗方式结合时，抗肿瘤特性还会显著增强。而相较传统ADC，蛋白效应偶联物可以拥有更强的靶向毒性，更广的适应范围，可以应用于更多非肿瘤领域，如多数自免疾病。现在来看，靶向分子与药效蛋白发挥协同效应，明显可以产生1+1＞2的作用，达成更高效的治疗需求。但同时，由于药效蛋白与靶向分子的诸多链接限制，对于蛋白偶联物领域而言，也有不少值得进一步研究的内容。细胞因子药效蛋白偶联物的开始就现阶段而言，药效蛋白作为效应分子在偶联药物领域的例子并没有想象中那么多，近年来陆续出现的蛋白毒素、细胞因子与免疫细胞已是较为前沿的研究成果，而其中又以“细胞因子偶联物”的研究最具代表性。过去几十年，随着细胞因子的持续发现，其被广泛应用于抗肿瘤与抗感染方面，但与此同时，应用越广，其凸显出的局限性也越强，比如半衰期短，治疗窗口窄，毒副作用大等，这普遍存在于多数药效蛋白中。而抗体偶联细胞因子（immunocytokine），即通过特异性抗体将细胞因子引导至肿瘤微环境等疾病局部，再由细胞因子发挥其作用（如激活或者抑制免疫细胞），如此一来，可以有效降低肿瘤外毒性，以此扩大细胞因子的治疗窗口，因而，近年来也有越来越多的“抗体偶联细胞因子”相继进入临床阶段。品种原研单位许可单位靶点临床阶段 Nidlegy Philogen SpA 印度太阳药业有限公司 TNFA;EDB-FN;IL-2 注册申请 L19-TNF;Fibromun Philogen SpA - TNFA;EDB-FN 临床Ⅲ期 IBI-363 信达生物制药（苏州）有限公司 - IL-2;PD-1 临床Ⅱ期 RO6874281;simlukafusp alfa 罗氏制药 - AFAP1L2;FAP-alpha;IL-2 临床Ⅱ期 SAR-445877 赛诺菲 - IL15;PD-1 临床Ⅱ期 OXS-3550 University of Minnesota OXIS International Inc IL15;CD16;CD33 临床Ⅱ期 PF-06687234 Philogen SpA 辉瑞公司 IL10;CD29;EDA-FN 临床Ⅱ期 IBB-0979 盛禾（中国）生物制药有限公司 - IL10;CD276 临床Ⅱ期 SNG-2005 EMD Lexigen Research Center Corp;EMD Serono Inc Alopexx Oncology LLC CD20 临床Ⅱ期 APN-301 Apeiron Biologics GmbH;默克 - IL-2 临床Ⅱ期 ANV-419 Anaveon AG;University of Zurich - IL-2 临床Ⅱ期 TAK-573 武田药品工业株式会社 - IFN-alpha-2;CD38 临床Ⅱ期 Darleukin;L19-IL2 Philogen SpA Maastricht University Medical Center EDB-FN;IL-2 临床Ⅱ期 NHS-IL2-LT 默克 - IL-2;IL2R 临床Ⅱ期 STAR-0602 Marengo Therapeutics - TCRBV 临床Ⅱ期 RG-7835 罗氏制药 - CD25 临床Ⅱ期 IAE-0972 盛禾（中国）生物制药有限公司 - IL10;EGFR 临床Ⅱ期 F16IL2 PhiloGene Inc - IL-2;Tenascin 临床Ⅱ期 M-9241 默克 National Cancer Institute IL12R 临床Ⅱ期 PDS0301 PDS Biotechnology Corp - IL-12 临床Ⅱ期 IAP-0971 盛禾（中国）生物制药有限公司 - IL15;PD-1 临床Ⅱ期数据来源：药智数据截至目前，全球已有数十款在研的抗体偶联细胞因子药物，其有效载荷主要集中在IL-2，IFN-γ，EPO等类型。其中由Philogen开发的Nidlegy是抗体偶联细胞因子领域中进度最靠前的管线，目前已向欧洲药品管理局（EMA）提交了上市申请，一旦获批，或将成为第一款上市的抗体偶联细胞因子产品。而作为 Philogen 专有的生物制药产品，Nidlegy是专为治疗皮肤癌而设计。结构上由 L19IL2 和 L19TNF 组成，其中L19 抗体对纤连蛋白的额外结构域 B 具有特异性，其Ⅲ期PIVOTAL研究显示，治疗组复发或死亡风险降低了41%，中位RFS延长了一倍以上，且患者组实现病理学完全缓解（pCR）的比例为21%。而国内领域，研究进度较靠前的则是信达生物的一款PD-1/IL-2（IBI363），其采取非对称二聚体设计，IL-2经过改造保留CD25（IL2Rɑ）活性以最大化疗效和高选择性，同时减少对Rβγ 结合以降低系统毒性。既可以阻断PD-1/PD-L1免疫抑制通路，又可以通过IL-15激活免疫细胞；同时，PD-L1抗体还能将IL-15靶向到PD-L1+的肿瘤微环境，选择性激活肿瘤浸润CD8+T细胞和NK细胞，降低IL-15全身性副作用。综上可知，抗体偶联细胞因子的技术方向，因其强大的靶向肿瘤和延长细胞因子半衰期的能力，以及其对多个靶点的协同抗肿瘤作用，目前已经成为效应蛋白偶联物领域最具前景的疗法，成了创新biotech脱颖而出的重要资本。不过，尽管表面上看抗体偶联细胞因子领域似乎前景广阔，但对于“药效蛋白偶联物”领域而言，仍是成功的个别例子，占据极小的部分，放眼整个药效蛋白偶联领域，仍有大量药效蛋白缺乏有效的偶联方式。化学修饰+蛋白药效蛋白偶联物的未来就技术层面而言，如何想将任一蛋白进行修饰偶联，而不需要考虑药效蛋白的针对性与特殊性，是现阶段专家在研究中主要的思考方向。目前来看，通过化学偶联修饰方式与药效蛋白相结合是比较切实可行的方法。比如PEG/mPEG修饰、氨甲酰化修饰、硫酸化修饰与磷酸化修饰。 PEG/mPEG偶联蛋白所谓PEG，是一种被广泛应用于蛋白质和多肽等生物聚合物进行共价修饰的高分子材料；mPEG则是将PEG其中一端进行封端后的产物；而PEG/mPEG化修饰就是将其与药物共价结合，以改善药物的药代动力学、药效学和免疫学特性，从而增强其治疗效果的一种药物技术。通常情况下，PEG/mPEG由于提高水溶性、减少酶水解、降低毒性和免疫原性、延长体内半衰期、改变组织分布以及增加药物分子的靶向位点浓度等特点，被主要考虑用作生物分子偶联的起始材料。图片来源：西宝生物而在众多与PEG偶联的生物大分子中，脂类、蛋白质、小分子药物和其他疏水性聚合物已被广泛研究，并被用来制造用于药物输送和成像的纳米载体，对于蛋白质而言，其没有对蛋白种类的显示，简单来讲就是局限于细胞因子、免疫细胞等种类，理论上可以与所有蛋白质进行PEG偶联。在原理上，蛋白质的PEG修饰之所以有一系列优势，主要是由于蛋白质PEG修饰后，偶联物使原有蛋白质的分子量增大，空间结构发生改变，一方面可以是使其可以逃避肾小球滤过作用，在血液循环中停留更长的时间；另一方面修饰剂会使得蛋白质表面抗原决定簇掩盖起来，避开免疫系统识别；甚至修饰剂作用下，蛋白质药物还能不易被各种蛋白酶的攻击，降解速率明显降低。图注：聚乙二醇修饰蛋白示意图资料来源：键凯科技招股说明书从蛋白质PEG修饰到mPEG修饰，如今在该领域范围内，已经有了许多蛋白质的聚乙二醇化修饰物作为药物取得了较好的结果，可行性上得到了充分验证。 1991年，第一种经聚乙二醇化修饰的蛋白质类药物PEG-腺苷脱氨酶被FDA批准上市，用于治疗一种严重的儿童免疫缺陷症； 2001年，用聚乙二醇修饰的干扰素（PEG-INTRON）经FDA批准上市，用于治疗慢性丙型肝炎； 2010年，通过赖氨酸偶联进行聚乙二醇化的普瑞凯希Krystexxa（pegloticase）被FDA批准用于治疗痛风，实现每月一针的注射频率。 2024年，J.P. Morgan大会上，由 Ascendis Pharma 原研开发的一款在研 PTH 激素原药（TransCon PTH ）亮相，由母药 PTH(1-34) 和支链甲氧基聚乙二醇 (mPEG) 载体通过专有连接剂瞬时结合而成，正在开发用于治疗成人甲状旁腺功能减退症，可以实现24 小时的正常生理范围内提供稳定的 PTH 水平。并且，作为化学偶联修饰中最主要的存在，PEG/mPEG修饰还成功为化学修饰蛋白建立了良好的开端，也为后续企业更多在研化学修饰方法，提供了良好的模板，比如氨甲酰化、硫酸化、磷酸化等。小结总结来看，由于药效蛋白本身诸多优势，目前通过偶联方式将药效蛋白进行系列改装已成为了现实，最切实有用的方法可以参考“抗体+蛋白毒素、抗体+细胞因子”。但是，无论是细胞因子、蛋白毒素，还是免疫细胞，其都只能代表药效蛋白中较小部分，蛋白偶联仍存在明显的局限性与针对性，好在以PEG/mPEG为首的化学偶联修饰技术之下，研究者们似乎在寻找针对任何蛋白偶联方法上已经有了些许突破。未来，随着更多如PEG/mPEG化、氨甲酰化、硫酸化、磷酸化等化学偶联修饰方法的发现，整个药效蛋白市场或许也将发生巨大重构，我们拭目以待。来源 | 博药（药智网获取授权转载）撰稿 | 头孢责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

抗体药物偶联物多肽偶联药物蛋白降解靶向嵌合体

100 项与 ANV-419 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床2期	美国	Anaveon AG	2022-12-16
晚期恶性实体瘤	临床2期	法国	Anaveon AG	2022-12-16
晚期恶性实体瘤	临床2期	德国	Anaveon AG	2022-12-16
晚期恶性实体瘤	临床2期	意大利	Anaveon AG	2022-12-16
晚期恶性实体瘤	临床2期	西班牙	Anaveon AG	2022-12-16
皮肤黑色素瘤	临床2期	美国	Anaveon AG	2022-12-16
皮肤黑色素瘤	临床2期	法国	Anaveon AG	2022-12-16
皮肤黑色素瘤	临床2期	德国	Anaveon AG	2022-12-16
皮肤黑色素瘤	临床2期	意大利	Anaveon AG	2022-12-16
皮肤黑色素瘤	临床2期	西班牙	Anaveon AG	2022-12-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ANV419-001 (AACR2022)	临床1/2期	肿瘤	-	ANV419	觸蓋願襯壓壓鹽衊鏇願(醖範齋繭壓壓鏇壓鹹夢) = 積襯簾觸憲窪遞獵蓋衊繭廠鑰醖觸糧觸齋選鹽 (夢鑰鹽餘鹹衊膚選鏇鑰 ) 更多	-	2022-06-15
SITC2021	临床1期	-	2	ANV419 0.03 mg/kg	醖鹹衊鬱網醖鏇憲獵鑰(襯遞淵窪構艱築蓋糧築) = mild systemic inflammatory response was observed at 0.3 mg/kg evidenced by a transient increase of CRP on days 4 and 19 築膚蓋鑰鹽鏇齋選積鏇 (壓構淵遞觸艱壓窪膚窪 ) 更多	积极	2021-11-10
SITC2021	临床1期	-	2	ANV419 0.1 mg/kg		积极	2021-11-10